Atea Pharmaceuticals (AVIR) investor relations material

Executive summary

• Positive topline results from the Phase 3 C-BEYOND trial for BEM/RZR in HCV, meeting primary and secondary endpoints and demonstrating statistical non-inferiority to SOF/VEL, with robust efficacy and an 8-week regimen for non-cirrhotic patients.

• C-FORWARD Phase 3 trial outside North America is fully enrolled with over 880 patients; topline results expected early Q1 2027, supporting a potential NDA submission in Q2 2027 if positive.

• Initiated Phase 1 clinical trial for AT-587 targeting chronic HEV in immunocompromised patients, with dose escalation ongoing and first cohort completed.

• No products approved or commercial revenue to date; focus remains on advancing pipeline and preparing for commercialization.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $219.5 million as of June 30, 2026, down from $301.8 million at year-end 2025, expected to fund operations through 2027.

• Net loss for Q2 2026 was $32.9 million, or $0.41 per share, compared to $37.2 million, or $0.44 per share, in Q2 2025; net loss for the first half of 2026 was $78.4 million, up from $71.4 million in the prior year period.

• Operating expenses for Q2 2026 were $35.1 million, down from $41.3 million in Q2 2025, driven by lower R&D and G&A costs.

• R&D expenses increased year-over-year due to higher external spend on HCV phase III and HEV clinical activities, partially offset by lower internal costs.

• Working capital was $200.5 million as of June 30, 2026; total assets $232.3 million, total liabilities $28.1 million, and stockholders’ equity $204.2 million.

Outlook and guidance

• NDA submission for BEM/RZR in HCV anticipated in Q2 2027, pending positive C-FORWARD results.

• Cash runway expected through 2027, enabling completion of key milestones and advancement of HEV candidate.

• Expects a short time to profitability after a projected mid-2028 launch.

• Initiation of PoC clinical study for AT-587 planned for 1H 2027.

• Open to strategic transactions and collaborations to maximize shareholder value.